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WE WILL TRY to cover three general areas of clinical The above series was compiled at a time when practical 
interest by providing: a) a brief summary of accomplish- methods of donor-recipient matching were not available, 
ments which have already been possible with the admit- except for the assurance of compatible blood types. The 
tedly imperfect immunosuppressive regimens now in use; results, therefore, were obtained with relatively random 
b) a critique of the drugs or drug combinations currently donor selection from related and unrelated populations. 
being employed; and c) a brief description of research Since that time, clinically usable techniques have been 
which suggests that heterologous antilymphoid serum developed for measuring antigens in the human lympho- 
derivatives may be of clinical value in the future. cytes, one system being that of Terasaki and co-workers 
of Los Angeles (16). Since most antigens in the white cells 
PAST EXPERIENCE are shared in other tissues including the kidney, the 
demonstration of close compatibility in the leukocytes of 
Interest in the practical application of homografting a donor-recipient pair might be predicted to be a favor- 
procedures is justified by the chronic survival which has able prognostic + providing the antigens being studied 
already been attained by many patients after renal homo- had any relation to histocompatibility. Terasaki's retro- 
transplantation. In Denver, for example, a series of 6.4 spective studies of the original Denver series provided 
consecutive uremic patients was treated from November evidence that this was the case. ~h~ truly 
1 9 ~ 2  to March 1 9 ~ 4  with homografts Obtained clinical results in the chronic survivors were in those 
from volunteer living donors. A follow-up on these patients shown to have received a kidney from a well- 
recipients is now available (to October 1966) of 31-47 matched donor (1.5). The kidney injury found in biopsies 
months. ~xac t ly  half of the ~at ients  are still alive (Fig. 1). these homografts after 2  years was inversely related to After a very steep early mortality, the life survival curve the quality of the antigen compatibility 
has been relatively stable. Similar long-term results in B~~~~~~ of these suggestive findings, donor selection 
large series have been Hume et (4) and for subsequent cases has been made by Terasaki on the 
Hamburger et al. (2). basis of the best available antigen match (16). The selec- 
In our experience, a most important determinant of the tivity which was possible for transplantation between 
ultimate outcome has been the source of the homograft, relatives was, of course, limited by small numbers, for 
as demonstrated by a breakdown of the foregoing series. which reason the matching actually achieved was little Twenty-nine of those patients who received kidneys from better than could be obtained by random intrafamilial 
blood relatives (excluding identical twins) are still alive pairing. ln contrast, the donor pool of go-roo in the (63 % )  Only deaths have occurred from the 6th nonrelated cases permitted a considerable improvement 
month onward, one of these as the consequence of choice to that previously possible. 
cardial infarction after 32 months in a patient with excel- 
~ ~ ~ ~ ~ ~ - ~ i ~  cases have been studied with these new 
lent kidney function. In contrast, only 3 of the 18 recip- conditions, half with related and half with nonrelated ients of nonrelated kidneys survive to date. In the latter donors. ~h~ survival for the first I 4  postoperative months 
group, the early mortality was high, and unlike the situa- was the same for both groups (Fig. 3 ) .  One of the re- 
tion with related cases, the chance of late death remained cipients of a nonrelated homograft died of hepatitis 
significant (Fig. 2 ) .  after 17.5 months. All others from both series were still 
alive after I 5 months to 2 years. 
1 This study was aided by Public Health Service Grants AM Although the above data suggest that typing permits 
06283> AM 0~344, HE O7735> AM 07772> 04152, Oo051 discrimination of suitable donors, particularly for non- 
and FR 00069. 
2 Markle Scholar. related cases, it is unlikely that such techniques will 
3 Present address: Chiba, Japan. eliminate an inherent and unsatisfactorily high mortality. 
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FIG. I .  Life survival curve of 
the first 64 patients treated with 
renal homotransplantation from 
November 1962 to March 1964. 
All donors were living volunteers. 
Recipients now have been fol- 
lowed for 2.5 to almost 4 years. 
Exactly one-half of the patients 
were still alive a t  the end of 
September I 966. 
FIG. 2. Breakdown of the 
results shown in Fig. I according 
to the source of the homograft. 
Note that 6376 of the patients 
who had consanguineous donors 
were still alive compared to only 
3 of 18 who received nonrelated 
kidneys. 
The reason is that virtually all of the deaths in the later 
series, and most of those in the original group as well, 
were due to the irll~nunosuppressive agents used to pre- 
vent rejection, and not through failure to control this 
process. 
CRITIQUE OF IMMUNOSUPPRESSIVE REGIMENS 
The foregoing point can be easily demonstrated by a 
study such as that illustrated ill Fig. 4. In this study, 18 
dogs had removal of one of their kidneys and transfer of 
the other organ to the contralateral iliac fossa, in essence 
providing them with a perfectly matched transplant. 
They were then treated with azathioprine in the same 
way as if ho~llotransplantation had been done. The life 
survival curve was remarkably similar to that previously 
demonstrated in the clinical series. Infectious disease 
con~plications were the chief causes of death. A con- 
tributory factor often appeared to be liver injury. I t  is 
known that azathioprine is markedly hepatotoxic agent 
(Fig. 5) in dogs (14), although the evidence is tenuous 
that it similarly affects the human liver (3). 
Description of these experiments does not imply dis- 
satisfaction with azathioprine which is the single best 
immunosuppressive agent available today. Patients who 
can be effectively treated with this drug alone are re- 
markably well. Unfortunately, therapy solely with 
azathioprine is usually insufficient to prevent homograft 
repudiation. It is the necessity for additional treatment 
which imposes great risk. The use of prednisone, the 
most effective drug to control and reverse rejection, has 
created the most serious problems. 
The way in which such combination drug therapy 
contributes to survival or to death can best be appreci- 
ated from specific examples. In Fig. 6 the course of a 
patient is illustrated who was operated upon in April 
1963. He had immediate diuresis of the homograft and 
excellent subsequent renal function which continued for 
2 weeks. At that time rejection developed in spite of 
therapy with azathioprine. There was swelling of the 
transplant, deterioration of renal function, and fever. All 
of these adverse findings were reversed with the institu- 
tion of 2 0 0  rng/day of prednisone. 
In this patient it became possible to reduce and after 
5 months to discontinue prednisone. During the 3 ensu- 
ing years the patient has received only azathioprine, 
that drug which at the beginning was insufficient to 
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prevent rejection. The serial events show, first, that 
rejection is a reversible process and, second, that some 
change in the host-graft relationship transpires ulti- 
mately allowing relaxation in many patients of the 
stringency of immunosuppression. In animal experiments 
it has been shown that the change is complete enough 
to allow survival for years after discontinuance of all 
therapy. The frequency with which this might be ex- 
pected in man is not known. 
The early need for maximum immunosuppression is 
the most important etiology of failure as shown in Fig. 7. 
As in the previous case, this patient received a fraternal 
homograft. There was good initial function followed by a 
very severe rejection and temporary anuria. The addition 
of high dose steroid therapy was followed by return of 
urine excretion. After it appeared that the worst of the 
rejection crisis had passed, the patient died from bone 
marrow depression and sepsis. Here, overdosage with 
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FIG. 3. Results of renal transplantation in a more recent series of 
patients whose donors were selected by Terasaki's antigen-match- 
ing method. Note that survival after 13  months was exactly the 
same in both the related and nonrelated cases. Compare with 
results shown in Fig. 2 .  
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PIG. 4. Life survival curve of 18 dogs which received renal auto- 
grafts and subsequent therapy with azathioprine. 
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FIG. 5. Toxicity of azathioprine when used alone, with 35S- 
methionine, and with L-mnethionine. Six dogs were in each of the 
three test groups depicted. Despite the abnormalities of liver func- 
tion, jaundice did not develop. (By permission of C. V. Mosby Co., 
from Starzl et al. Surgery 58: 131,1965.) 
CCr 100 
L* 
TlME IN DAYS 
FIG. 6. Classical rejection crisis in patient treated with drugs 
alone. Deterioration of renal function began 1 9  days after trans- 
plantation. All stigmata of rejection are present except for acute 
hypertension and weight gain, which were successfully prevented 
by medical treatment. Acti-C = Actinomycin C;  LN = Left 
nephrectomy at time of transplantation; RN = Right nephrec- 
tomy. Imuran is synonymous with azathioprine. (By permission 
of Surg. Gynecol. Obstet. I 1 7 :  385, 1963,) 
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azathioprine was the irnrliediate cause of death. The in- 
tensive steroid therapy played a secondary role. 
Such acute toxicity with azathioprine has been virtu- 
ally elinlinated since it is now thoroughly appreciated 
that this drug and its by-products are partially excreted 
in the urine. With the deterioration of renal function 
that accorllpanies a severe rejection crisis, it is often 
necessary to reduce the dose. No such simple formula to 
decrease the hazards of steroid therapy is available. 
In  many cases it is found that continued function of a 
homograft is dependent upon continuation of unac- 
ceptably large quantities of prednisone. The complica- 
tions which follow are exceedingly troublesonle at best, 
and lethal at worst. These include cosnletic deformity, 
bone demineralization often with spontaneous fractures, 
111uscle wasting, arrest of growth in infants, fatty infiltra- 
tion of the liver, pancreatitis, and gastrointestinal ulcera- 
tion and hemorrhage to name just a few. Most serious, 
however, is the consequent susceptibility to microorgan- 
isms of all types. 
If the res~~ltant  infections are due to corurnon patho- 
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FIG. 7. Typical unsuccessfully treated case. The donor and 
recipient were brothers, both of A+  blood type. A violent rejec- 
tion crisis followed good early function, and anuria developed 
which lasted z weeks. Although the rejection was reversed and a 
secondary diuresis began, the patient died from drug toxicity, 
leukopenia, and septicemia. Acti C = Each arrow is ZOO pg 
intravenous actinomycin C. (By permission of C. V. Mosby Co., 
from Starzl et al. Surgery 56 : 296, I 964.) 
genic bacteria they can be treated effectively with prop- 
erly chosen antibiotics. Very often, however, these are 
caused by fungi, protozoa, or viruses for which specific 
therapy is not available. The tragic consequences are 
illustrated in Fig. 8. This patient, who received a homo- 
graft from his brother, had an early rejection crisis fol- 
lowed by excellent renal function for the next g months. 
After reduction of his prednisone to lo  mg/day, he had 
a delayed rejection which was controlled by increasinq 
the prednisone dose to a level from which subsequent 
withdrawals were not possible without further deteriora- 
tion of kidney function. He died 15 months later but not 
from renal failure. He had fatty infiltrations of the liver, 
a duodenal ulcer, and pancreatitis. There were cyto- 
niegalic inclusion viruses in the lungs and liver, and dif- 
fuse pneurllonitis due to Pneumocysti.~ carinii and Askergillus 
fumigatum. 
HETEROLOGOUS ANTILYMPHOID SERUM 
We would now like to discuss some recent studies which 
could conceivably lead to improven~ent in patient care. 
These investigations have been with heterologous anti- 
lymphoid serum or its globulin derivatives. Waksrnan 
et al. (I  7) and Woodruff ( I  8, I g) were the first to suggest 
the possible value of such substances for mitigation of 
homograft rejection. Their predictions have been amply 
confirmed by several other investigators ( I ,  6-1 I ) ,  also 
working with inbred mice, guinea pigs, or mice treated 
with serum raised in the rabbit. Skin grafts were used as 
the test system. Our efforts have been oriented to the 
testing of these biologic materials for protection of whole 
organ grafts, and to the development of a product which 
could practically and safely be given to rnan (5). 
Serum was raised in horses which were subcutaneously 
inoculated with lymphocytes from the lymph nodes or 
spleens of dogs, or alternatively with cadaveric human 
lymph nodes, thymuses, and spleens. When large num- 
bers of cells (10-196 billion) were injected weekly or 
even more often, leukoagglutinating titers in the equine 
serum rose to as high as I : 16,000 within 20-75 days. 
The serum or plasma collected from these horses and 
injected unchanged into dogs' peritoneal cavities was 
toxic, causing death in 30 %' of the animals treated daily 
for 2 weeks. Nevertheless, the prolongation of renal 
homograft survival in those dogs that did not die from 
treatment was significant. 
A critical step in reducing toxicity was absorption of 
the horse serum with canine red cell pack and serum. 
When the hernagglutinins and precipitins were thus 
removed, it was possible largely to eliminate the acute 
anemia which the original product had caused. Further- 
more, injections by either the intraperitoneal or sub- 
cutaneous routes did not cause death. Further absorption 
with canine liver and kidney markedly reduced the 
leukoagglutinating titer without increasing the safety. 
The location of the leukoagglutinating antibodies was 
studied by column chromatography, electrophoresis, 
and immunoelectrophoresis (5). The activity was in the 
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FIG. 8. Course of a 37-year-old man who received a kidney fro111 penia or make easier the subsequent management; the post- 
his younger brother. Both were A+  blood type. Note the severe thymectorny changes in lymphocyte counts were related to adjust- 
late rejection after g months and the subsequent slow deterioration ments in steroid dosage. (By permission of Ann. ,$'. k'. Acad. Sci. 
of renal function. Late thynlecto~rly did not induce either lyn~pho- 129: 598, 1966.) 
UNABSORBED HORSE 
ANTI - HUMdN LYMPHOiD 
S E R U M  
rrc. 9. Studies of the leukoagglutinin- 
containing fractions in antihuman-lym- 
phoid serum employing column chro~natog- 
raphy, electrophoresis, and irnmuno- 
electrophoresis. Various eluates from the 
DEAE-cellulose column were analyzed 
spectrophotometrically for protein content 
(expressed as optical density), and the 
presence or absence of leukoagglutinins 
determined for each collection tube. 
Electrophoresis and im~nunoelectrophore- 
sis permitted relatively complete classifica- 
tion of the active immunoglobulins. (By 
permiission of Surg. Gynecol. Obstet. 124: 
1. 1967.1 
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gaInma and T-equine globulin fractions, and to a lesser 
extent in the beta globulin (Fig. 9). 
Amn~oniurn sulfate precipitation at 0.4 saturation was 
used to rernove these co~nponents in bulk for biologic 
testing. The electrophoretic and i~nmunoelectrophoretic 
qualities of a batch of antihuman-lymphoid globulin 
obtained with two precipitations is shown in Fig. 10. 
The plasma, serurn, and globulin prepared fro111 the 
blood of immunized horses all caused lynlphopenia as 
rIc. I o. Electrophoresis and i~ur~~unoelectrophoresis of absorbed 
antihunxln-lymphoid serum and the protein obtained from it by 
two precipitations with 0.4 saturated ammonium sulfate, two 
dialyses and lyophilization. The final product, which was used 
clinically, consists almost entirely of gamnla G globulin. (By 
pernliss~on of Surg. Cynecol. Obstet. 124: I ,  1967.) 
compared to the absence of this effect in control dogs 
(Fig. I I ) .  A further important difference was noted. The 
canine precipitin titer against horse protein either did not 
rise or increased sluggishly to low levels when the immune 
serum or globulin was administered daily, compared to 
rapid high rises with conlparable doses of norrnal serurn. 
These findings suggested that the risk from serurn sick- 
ness might be less with antilymphoid materials than 
might otherwise be feared, due presumably to their 
irnnlunosuppressive qualities. 
I t  has, in fact, been found that dogs tolerate daily in- 
jections of the antilymphoid substances for months with- 
out overt toxicity if the serum has initially been absorbed 
with red cells and serum. Changes were not seen in 
either standard liver or renal function tests. However, 
renal biopsies revealed electron-micrographic densities 
in the glomeruli of a significant percent of kidneys from 
these animals, providing a clear warning that clinical use 
of such agents might have to be on a short-term basis (5). 
The protective effect upon canine renal homografts of 
immune horse plasma, serurn, and globulin has been 
extensively evaluated ( I  3). The results are surn~narized 
in Fig. 1 2  with statistical computations that lirnit survival 
credit for any individual dog to 70 days. All three agents 
significantly prolonged survival providing therapy was 
given before as well as after transplantation. The effect 
was inconstant when treatment was confined to the post- 
transplant period and it was not demonstrable if injec- 
tions were only given preoperatively. All kidneys were 
eventually rejected, the maxirnurn survival being 144 
days. 
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i:rc. I I .  Effect of horse plasrna or serum and crude horse agents were prepared from horses imrrlunized against dog lym- 
globulin upon the hen~atocrit, lymphocyte count, total white phoid tissue. Note that acute anernia was largely prevented only 
coutlt, and white count differential during 15 days of daily ad- when complete absorption had been carried out with canine red 
ministration. I n  all but the control experiments on the right, the cell pack. (By permission of Surg. G~necol. Obstet. 124: I ,  1~67 . )  
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FIG. I 2. Summary of survival (days) in 80 dogs with renal trans- 
plantation treated with antilymphoid plasma, serum, or globulin. 
Note that thymectomy was not useful, and that the best results 
were with treatment before and after operation. PreRx = treat- 
ment before and after. No PreRx = treated only after. PreRx 
only = therapy solely before operation. No PreRx + Aza = 
globulin and azathioprine both started at time of transplantation. 
Details and statistical analyses have been published (13). 
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FIG. I 3. Effect of antilymphoid serum or globulin upon survival 
after orthotopic liver transplantation. For both these mean values 
and those in Fig. 12, dogs living longer than 70 days were given a 
70-day survival credit. 
Prolongation of survival after orthotopic homotrans- 
plantation of the canine liver was also easily demon- 
strable (Fig. 13), apparently with a somewhat greater 
regularity than with renal hornografts. The mean sur- 
vival values depicted are computed with a limitation of 
70 days credit for any individual animal, but three of 
these dogs are still alive after 4-6 months. The course of 
one illustrates two important points (Fig. 14). First, it 
was not necessary to have prolonged lymphopenia for 
success. Second, rejection did not necessarily follow ces- 
sation of therapy, or if it did, it was often indolent in its 
development. The animal whose course is depicted has 
not received any treatment for Inore than 5 months. 
These studies provided some guidelines for the clinical 
application of antilymphoid agents. It  seemed clear that 
an immunosuppressive effect was present, but that this 
was too incomplete to warrant sole or even primary de- 
pendence upon such therapy. In addition, it was thought 
that the threat of serum toxicity inight preclude long- 
term treatment. Consequently, a clinical trial was given 
horse antihuman-lymphoid globulin as an adjuvant 
agent. It  was started in intramuscular injections from 5 
to 35 days before operation and continued thereafter as 
shown in Fig. 15. Therapy with azathioprine was given 
in the customary way. During the 1st postoperative 
month prednisone was administered only if required for 
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FIG. 14. A chronically surviving dog which was treated before lymphocytosis late in the postoperative period. The animal is in 
and for 2 0  days after orthotopic liver transplantation with intra- excellent health after almost 6 months. (By permission of Surg. 
peritoneal antilymphoid serum (ALS). Note the pronounced Gynecol. Obstet. 124: 301, 1967.) 
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rICr. I 5. Course of a patient treated before and after renal homo- 
transplantation with antilymphoid globulin. No rejection oc- 
curred. Note the rises in precipitin and hemagglutinin titers, 
findings which prompted institution of prednisone therapy. These 
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FIG. 16. Variations in i~llnlunosuppression and renal function 
during the first 63 postoperative days in four successive groups of 
patients who received kidneys from blood relatives. Since the blood 
urea nitrogen and creatinine clearance were not determined each 
day, these were cornpiled on a weekly basis. Those in series 4 
received adjuvant therapy with antilyrnphoid globulin. Note the 
drastic reduction in average prednisone dose which was achieved 
in these patients without significant loss of renal function. Progres- 
sive dinlinution of azathioprine dosage in the succeeding series is 
evident. (By permission of Surg. Gynecol. Obstet. 124: 301, 1967.) 
the treatment of rejection. After this time, small steroid 
doses were started even if rejection had not occurred. 
Eight patients with hornotransplantation from related 
donors have been treated with this regimen. All eight are 
32 36 40 44 48 52 56 60 64 68 7'2 7'6 80 64 
TIME IN DAYS 
titers subsequently fell. This patient had a good antigen match 
with his sibling donor. (By permission of Surg. Gynecol. Obstet. 
124:'301, 1967.) 
well from 2 to 3.5 rnonths after operation. The conva- 
lescence in these cases was compared with that observed 
in three similar groups of patients treated in the past. 
The conditions of cross analysis and the other details of 
this study are fully described elsewhere (13), but some 
brief summary comments are in order. 
The most striking change was that thc amount of 
prednisone necessary during the first g weeks of conva- 
lescence was considerably less than half of that used in any 
previous series (Fig. 16). The doses of azathioprine were 
also smaller. This reduction in standard irnmunosuppres- 
sion was not paid for with a loss of homograft function 
(Fig. 16). The pooled results of daily BUN and creatinine 
clearance in the three retrospective control groups were 
not significantly different than in the antilymphoid glob- 
ulin series. Life-threatening toxicity has not yet been ob- 
served, although fever and injection-site tenderness were 
seen in almost every case. For the complete data as well 
as a discussion of the validity and interpretation of these 
observations, the reader is referred to a complete account 
of the results ( I  3). 
Thus far, there appears to have been sorne benefit dur- 
ing the critical early postoperative period when the 
mortality has been the greatest in all clinical series, here 
and elsewhere. Whether this gain will be canceled by a 
later morbidity is an open question. Meanwhile, it is 
important to stress the experimental nature of anti- 
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lymphoid globulin therapy in view of the unknown risk SUMMARY 
f i ok  serum sickness.  he &lagnitude of this hazard and 
the related question of serum nephrotoxicity alluded to 
earlier can be completely assessed only with further ob- 
servation and by study of renal homograft biopsies in 
those patients now under treatment. Wider clinical trial 
is not recommended until this information has been 
obtained. 
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